© Reuters. FILE PHOTO: The GlaxoSmithKline (GSK) logo is seen on top of GSK Asia House in Singapore, March 21, 2018. Picture taken March 21, 2018. REUTERS/Loriene Perera/File Photo
By Ludwig Burger
(Reuters) - GlaxoSmithKline (NYSE:GSK) on Thursday said that a lab analysis of the antibody-based COVID-19 therapy it is developing with U.S. partner Vir has shown the drug is effective against the new Omicron variant.
In a statement, the British drugmaker said that lab tests and a study on hamsters have demonstrated the sotrovimab antibody cocktail to work against viruses that were bio-engineered to carry a number of hallmark mutations of the Omicron variant.
The tests are ongoing to confirm the results against all of the Omicron mutations with an update expected by year-end, it added.
Separately, Britain's drug regulator on Thursday approved sotrovimab, also known under the brand name Xevudy, for people with mild to moderate COVID-19 who are at high risk of developing severe disease.
The Medicines and Healthcare products Regulatory Agency (MHRA) recommended use of Xevudy as soon as possible and within five days of the onset of symptoms.
Marketmind: Vol takes a toll By Reuters
Grab's $40 billion Nasdaq debut to set tone for Southeast Asian tech listings By Reuters
Related News
